CDA Formulations to Make Surgery A Top Choice of Cancer Therapy
Ming C Liau, Christine L Craig, Linda L Baker
The objective of this article is to promote surgery as a top choice of cancer therapy. Surgery is obviously
a top choice of cancer therapy when cancer stem cells (CSCs) and cancer cells (CCs) are confined to
the primary site, and chemo-surveillance and immune-surveillance are still functioning to prevent the
dissemination of metastasis. Surgical therapy of cancer is instant following the healing of surgical
wounds which comes naturally within a week or two weeks. But if metastasis has occurred, surgery is no
longer an option, because surgical wounds tend to promote dissemination of metastasis. Metastasis is
the making of CSCs. If CSCs can be effectively put under control to prevent metastasis, then surgery is
still a top choice of cancer therapy even metastasis has taken place. Cell differentiation agent-2 (CDA2) is a preparation of wound healing metabolites purified from freshly collected urine by reverse phase
chromatography on XAD-16, which has been approved by the Chinese FDA as an adjuvant agent for
breast, non-small cell lung cancer and primary hepatomas in 2004, and as a mono-therapeutic agent for
myelodysplastic syndromes (MDSs) in 2017. MDSs are diseases attributable entirely to CSCs. CDA-2 is
obviously the best drug for the therapy of CSCs. The active components of CDA-2 include differentiation
inducers (DIs), differentiation helper inducers (DHIs) to target abnormal methylation enzymes (MEs),
and phenylacetylglutamine as an effective anti-cachexia chemical to restore chemo-surveillance. We
have carried out extensive studies on natural and non-natural DIs and DHIs to make CDA formulations
effective for the induction of terminal differentiation of CSCs and CCs, which are definitely helpful to
promote surgery as a top choice of cancer therapy.
